Katja Selin

Katja Selin

Auto-generated profile, based on publicly available information

Katja Selin

Department of Medicine Solna, Karolinska Institutet

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
EVEduardo Villablanca
Eduardo Villablanca
KSKatja Selin
Katja Selin
CHCharlotte Hedin
Charlotte Hedin

11 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSara M. Parigi
Sara M. Parigi
LLLudvig Larsson
Ludvig Larsson
SDSrustidhar Das
Srustidhar Das
RFRicardo O. Ramirez Flores
Ricardo O. Ramirez Flores
AFAnnika Frede
Annika Frede
EVEduardo Villablanca
Eduardo Villablanca
The intestinal barrier is composed of a complex cell network defining highly compartmentalized and specialized structures. Here, we use spatial transcriptomics to define how the transcriptomic landscape is spatially organized in the steady state and healing murine colon. At steady state conditions, we demonstrate a previously unappreciated molecular regionalization of the colon, which dramatically changes during mucosal healing. Here, we identified spatially-organized transcriptional programs defining compartmentalized mucosal healing, and regions with dominant wired pathways. Furthermore, we showed that decreased p53 activation defined areas with increased presence of proliferating epithelial stem cells. Finally, we mapped transcriptomics modules associated with human diseases demonstrating the translational potential of our dataset. Overall, we provide a publicly available resource defining principles of transcriptomic regionalization of the colon during mucosal healing and a framework to develop and progress further hypotheses.

7 May 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
KSKatja A Selin
Katja A Selin
CHCharlotte Hedin
Charlotte Hedin
EVEduardo J Villablanca
Eduardo J Villablanca
Current practice in IBD is to classify patients based on clinical signs and symptoms and provide treatments accordingly. However, the response of IBD patients to available treatments is highly variable, highlighting clinically significant heterogeneity among patients. Thus, more accurate patient stratification is urgently needed to more effectively target therapeutic interventions to specific patients. Here we review the degree of heterogeneity in IBD, discussing how the microbiota, genetics, and immune system may contribute to the variation among patients. We highlight how molecular heterogeneity may relate to clinical phenotype, but in other situations may be independent of clinical phenotype, encouraging future studies to fill the gaps. Finally, we discuss novel stratification methodologies as a foundation for precision medicine, in particular a novel stratification strategy based on conserved genes across species. All of these dimensions of heterogeneity have potential to provide strategies for patient stratification and move IBD practice towards personalised medicine.

9 September 2020 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Open access
KKKatja A. Kulmala
Katja A. Kulmala
JBJan Björk
Jan Björk
SASara Andersson
Sara Andersson
ABAnn-Sofie Backman
Ann-Sofie Backman
MEMichael Eberhardson
Michael Eberhardson
CHCharlotte Hedin
Charlotte Hedin
Effects of nutritional intake on inflammatory bowel disease (IBD) flare resolution are unknown. We hypothesised that nutritional factors during hospitalisation for acute severe IBD are associated w...

29 October 2024 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
KSKatja Anneli Selin
Katja Anneli Selin
SASara Andersson
Sara Andersson
KBKatarina Bilén
Katarina Bilén
HSHans Strid
Hans Strid
JBJan Björk
Jan Björk
CHCharlotte R. H. Hedin
Charlotte R. H. Hedin
Objectives: The optimal nutritional management during a severe flare of inflammatory bowel disease is uncertain. The goal of this study was to describe variations in nutritional practices between different countries, professions and types of hospitals, as well as between ulcerative colitis (UC) and Crohn’s disease (CD). Methods: In this cross-sectional study, a novel questionnaire was distributed in the ECCO Congress 2022 and via ECCO country representatives. Results: The survey was completed by 313 participants. In total, 68% of the respondents were physicians. No specific nutritional screening tool was used by 45% of respondents. Almost a quarter of respondents reported less than 25% of patients being assessed by a dietitian in the first 3 days of a flare. The most common form of nutritional therapy was oral nutritional supplements (ONS) with easy-to-digest food. Total parenteral nutrition (TPN) was used by 10% of respondents for UC patients and 7% for CD. Energy intake, stool frequency and inflammatory biomarkers were the most common factors in determining when to change nutritional therapy. There were significant differences between different countries and health care professions for all the outcomes (P < 0.05). Nutritional management did not generally vary according to hospital type (university vs. general). During the first 3 days of a flare, a diet consisting exclusively of ONS was significantly more frequently used for CD than UC (P = 0.018). Otherwise, similar nutritional therapy strategies were reported for CD and UC, including using TPN to a similar extent. Conclusion: There is significant variation in nutritional management practices. Country is the main determinant of differences in practice.